Extracellular galectin-3 in tumor progression and metastasis

Frontiers in Oncology

Volumn 4 JUN, Issue , 2014, Pages

  Fortuna Costa, Anneliese ^a   Gomes, Angélica M ^a   Kozlowski, Eliene O ^a   Stelling, Mariana P ^a   Pavão, Mauro S G ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Cancer; Galectin 3; Glycosylation; Lattices; Metastasis; Mgat5; Tumor microenvironment

Indexed keywords

GALECTIN 3; GLYCAN DERIVATIVE; MEMBRANE PROTEIN; N ACETYLGLUCOSAMINYLTRANSFERASE; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; BONE MARROW; CELL ADHESION; CELL CYCLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL SURFACE; ENDOTHELIUM CELL; GLYCOSYLATION; HUMAN; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT;

EID: 84904597462     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00138     Document Type: Review

References (102)

1. Di Lella S, Sundblad V, Cerliani J, Guardia C, Estrin D, Vasta G, et al. When galectins recognize glycans: from biochemistry to physiology and back again. Biochemistry (2011) 50(37):7842-57. doi: 10.1021/bi201121m
2. Liu F-T, Rabinovich G. Galectins as modulators of tumour progression. Nat Rev Cancer (2005) 5(1):29-41. doi:10.1038/nrc1527
3. Newlaczyl A, Yu L-G. Galectin-3 - a jack-of-all-trades in cancer. Cancer Lett (2011) 313(2):123-8. doi:10.1016/j.canlet.2011.09.003
4. Hsu D, Zuberi R, Liu F. Biochemical and biophysical characterization of human recombinant IgE-binding protein, an S-type animal lectin. J Biol Chem (1992) 267(20):14167-74.
5. Moutsatsos I, Wade M, Schindler M, Wang J. Endogenous lectins from cultured cells: nuclear localization of carbohydrate-binding protein 35 in proliferating 3T3 fibroblasts. Proc Natl Acad Sci U S A (1987) 84(18):6452-6. doi:10.1073/pnas.84.18.6452
6. Yu F, Finley R, Raz A, Kim H-RC. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem (2002) 277(18):15819-27. doi:10.1074/jbc.M200154200
7. Paron I, Scaloni A, Pines A, Bachi A, Liu F-T, Puppin C, et al. Nuclear localization of Galectin-3 in transformed thyroid cells: a role in transcriptional regulation. Biochem Biophys Res Commun (2003) 302(3):545-53. doi:10.1016/S0006-291X(03)00151-7
8. Sato S, Hughes R. Binding specificity of a baby hamster kidney lectin for H type I and II chains, polylactosamine glycans, and appropriately glycosylated forms of laminin and fibronectin. J Biol Chem (1992) 267(10):6983-90.
9. Mehul B, Hughes R. Plasma membrane targetting, vesicular budding and release of galectin 3 from the cytoplasm of mammalian cells during secretion. J Cell Sci (1997) 110(Pt 10):1169-78.
10. Menon R, Hughes R. Determinants in the N-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum-Golgi complex. Eur J Biochem (1999) 264(2):569-76. doi:10.1046/j.1432-1327.1999.00671.x
11. Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta (2006) 1760(4):616-35. doi:10.1016/j.bbagen.2005.12.020
12. Takenaka Y, Inohara H, Yoshii T, Oshima K, Nakahara S, Akahani S, et al. Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett (2003) 195(1):111-9. doi:10.1016/S0304-3835(03)00056-9
13. Elad-Sfadia G, Haklai R, Balan E, Kloog Y. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem (2004) 279(33):34922-30. doi:10.1074/jbc.M312697200
14. Honjo Y, Nangia-Makker P, Inohara H, Raz A. Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res (2001) 7(3):661-8.
15. Nakayama R, Kuroda J, Taniyama N, Yamamoto-Sugitani M, Wada S, Kiyota M, et al. Suppression of SERPINA1-albumin complex formation by galectin-3 overexpression leads to paracrine growth promotion of chronic myelogenous leukemia cells. Leuk Res (2014) 38(1):103-8. doi:10.1016/j.leukres.2013.07.026
16. Kim H, Lin H, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res (1999) 59(16):4148-54.
17. Matarrese P, Tinari N, Semeraro M, Natoli C, Iacobelli S, Malorni W. Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. FEBS Lett (2000) 473(3):311-5. doi:10.1016/S0014-5793(00)01547-7
18. Takenaka Y, Fukumori T, Yoshii T, Oka N, Inohara H, Kim H-RC, et al. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol (2004) 24(10):4395-406. doi:10.1128/MCB.24.10.4395-4406.2004
19. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol (2000) 156(3):899-909. doi:10.1016/S0002-9440(10)64959-0
20. Nangia-Makker P, Wang Y, Raz T, Tait L, Balan V, Hogan V, et al. Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer (2010) 127(11):2530-41. doi:10.1002/ijc.25254
21. Khaldoyanidi S, Glinsky V, Sikora L, Glinskii A, Mossine V, Quinn T, et al. MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions. J Biol Chem (2003) 278(6):4127-34. doi:10.1074/jbc.M209590200
22. Boscher C, Zheng Y, Lakshminarayan R, Johannes L, Dennis J, Foster L, et al. Galectin-3 protein regulates mobility of N-cadherin and GM1 ganglioside at cell-cell junctions of mammary carcinoma cells. J Biol Chem (2012) 287(39):32940-52. doi:10.1074/jbc.M112.353334
23. Boscher C, Nabi I. Galectin-3- and phospho-caveolin-1-dependent outside-in integrin signaling mediates the EGF motogenic response in mammary cancer cells. Mol Biol Cell (2013) 24(13):2134-45. doi:10.1091/mbc.E13-02-0095
24. Zhang D, Chen Z-G, Liu S-H, Dong Z-Q, Dalin M, Bao S-S, et al. Galectin-3 gene silencing inhibits migration and invasion of human tongue cancer cells in vitro via downregulating ß-catenin. Acta Pharmacol Sin (2013) 34(1):176-84. doi:10.1038/aps.2012.150
25. Tsuboi K, Shimura T, Masuda N, Ide M, Tsutsumi S, Yamaguchi S, et al. Galectin-3 expression in colorectal cancer: relation to invasion and metastasis. Anticancer Res (2007) 27(4B):2289-96.
26. Machado C, Andrade L, Teixeira V, Costa F, Melo C, Dos Santos S, et al. Galectin-3 disruption impaired tumoral angiogenesis by reducing VEGF secretion from TGFß1-induced macrophages. Cancer Med (2014) 3(2):201-14. doi:10.1002/cam4.173
27. Yamamoto-Sugitani M, Kuroda J, Ashihara E, Nagoshi H, Kobayashi T, Matsumoto Y, et al. Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci U S A (2011) 108(42):17468-73. doi:10.1073/pnas.1111138108
28. Radosavljevic G, Jovanovic I, Majstorovic I, Mitrovic M, Lisnic V, Arsenijevic N, et al. Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity. Clin Exp Metastasis (2011) 28(5):451-62. doi:10.1007/s10585-011-9383-y
29. Feizi T. Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature (1985) 314(6006):53-7. doi:10.1038/314053a0
30. Gu J, Taniguchi N. Potential of N-glycan in cell adhesion and migration as either a positive or negative regulator. Cell Adh Migr (2008) 2(4):243-5. doi:10.4161/cam.2.4.6748
31. Sackstein R, Merzaban J, Cain D, Dagia N, Spencer J, Lin C, et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med (2008) 14(2):181-7. doi:10.1038/nm1703
32. Guo H-B, Johnson H, Randolph M, Pierce M. Regulation of homotypic cell-cell adhesion by branched N-glycosylation of N-cadherin extracellular EC2 and EC3 domains. J Biol Chem (2009) 284(50):34986-97. doi:10.1074/jbc.M109.060806
33. Dennis J, Lau K, Demetriou M, Nabi I. Adaptive regulation at the cell surface by N-glycosylation. Traffic (2009) 10(11):1569-78. doi:10.1111/j.1600-0854.2009.00981.x
34. Dennis J, Pawling J, Cheung P, Partridge E, Demetriou M. UDP-N-acetyl glucosamine:alpha-6-D-mannoside beta1,6 N-acetylglucosaminyltransferase V (Mgat5) deficient mice. Biochim Biophys Acta (2002) 1573(3):414-22. doi:10.1016/S0304-4165(02)00411-7
35. Demetriou M, Granovsky M, Quaggin S, Dennis J. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature (2001) 409(6821):733-9. doi:10.1038/35055582
36. Dennis J, Nabi I, Demetriou M. Metabolism, cell surface organization, and disease. Cell (2009) 139(7):1229-41. doi:10.1016/j.cell.2009.12.008
37. Ono M, Hakomori S. Glycosylation defining cancer cell motility and invasiveness. Glycoconj J (2004) 20(1):71-8. doi:10.1023/B:GLYC.0000018019.22070.7d
38. Guo H-B, Johnson H, Randolph M, Nagy T, Blalock R, Pierce M. Specific posttranslational modification regulates early events in mammary carcinoma formation. Proc Natl Acad Sci U S A (2010) 107(49):21116-21. doi:10.1073/pnas.1013405107
39. Kyselova Z, Mechref Y, Kang P, Goetz J, Dobrolecki L, Sledge G, et al. Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin Chem (2008) 54(7):1166-75. doi:10.1373/clinchem.2007.087148
40. Fernandes B, Sagman U, Auger M, Demetrio M, Dennis J. Beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res (1991) 51(2):718-23. 41. Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M, et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta (2002) 1572(2-3):232-54. doi:10.1016/S0304-4165(02)00311-2
41. Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M, et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta (2002) 1572(2-3):232-54. doi:10.1016/S0304-4165(02)00311-2
42. Partridge E, Le Roy C, Di Guglielmo G, Pawling J, Cheung P, Granovsky M, et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science (2004) 306(5693):120-4. doi:10.1126/science.1102109
43. Stillman B, Hsu D, Pang M, Brewer C, Johnson P, Liu F-T, et al. Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol (2006) 176(2):778-89. doi:10.4049/jimmunol.176.2.778
44. Iacobini C, Amadio L, Oddi G, Ricci C, Barsotti P, Missori S, et al. Role of galectin-3 in diabetic nephropathy. J Am Soc Nephrol (2003) 14:S264-S270. doi:10.1097/01.ASN.0000077402.95720.B4
45. Yu L-G, Andrews N, Zhao Q, McKean D, Williams J, Connor L, et al. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem (2007) 282(1):773-81. doi:10.1074/jbc.M606862200
46. Priglinger C, Szober C, Priglinger S, Merl J, Euler K, Kernt M, et al. Galectin-3 induces clustering of CD147 and integrin-ß1 transmembrane glycoprotein receptors on the RPE cell surface. PLoS One (2013) 8(7):e70011. doi:10.1371/journal.pone.0070011
47. Lajoie P, Partridge E, Guay G, Goetz J, Pawling J, Lagana A, et al. Plasma membrane domain organization regulates EGFR signaling in tumor cells. J Cell Biol (2007) 179(2):341-56. doi:10.1083/jcb.200611106
48. Markowska A, Jefferies K, Panjwani N. Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J Biol Chem (2011) 286(34):29913-21. doi:10.1074/jbc.M111.226423
49. Colin R. Galectins as modulators of cell adhesion. Biochimie (2001) 83(7):667-76. doi:10.1016/S0300-9084(01)01289-5
50. Ochieng J, Leite-Browning M, Warfield P. Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem Biophys Res Commun (1998) 246(3):788-91. doi:10.1006/bbrc.1998.8708
51. Ochieng J, Warfield P, Green-Jarvis B, Fentie I. Galectin-3 regulates the adhesive interaction between breast carcinoma cells and elastin. J Cell Biochem (1999) 75(3):505-14. doi:10.1002/(SICI)1097-4644(19991201)75:3<505::AID-JCB14>3.3.CO;2-9
52. Jiang K, Rankin C, Nava P, Sumagin R, Kamekura R, Stowell S, et al. Galectin-3 regulates desmoglein-2 and intestinal epithelial intercellular adhesion. J Biol Chem (2014) 289(15):10510-7. doi:10.1074/jbc.M113.538538
53. Markowska A, Liu F-T, Panjwani N. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J Exp Med (2010) 207(9):1981-93. doi:10.1084/jem.20090121
54. Fukushi J-I, Makagiansar I, Stallcup W. NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. Mol Biol Cell (2004) 15(8):3580-90. doi:10.1091/mbc.E04-03-0236
55. Alge-Priglinger C, André S, Schoeffl H, Kampik A, Strauss R, Kernt M, et al. Negative regulation of RPE cell attachment by carbohydrate-dependent cell surface binding of galectin-3 and inhibition of the ERK-MAPK pathway. Biochimie (2011) 93(3):477-88. doi:10.1016/j.biochi.2010.10.021
56. Dennis J, Granovsky M, Warren C. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta (1999) 1473(1):21-34. doi:10.1016/S0304-4165(99)00167-1
57. Boscher C, Dennis J, Nabi I. Glycosylation, galectins and cellular signaling. Curr Opin Cell Biol (2011) 23(4):383-92. doi:10.1016/j.ceb.2011.05.001
58. Lajoie P, Goetz J, Dennis J, Nabi I. Lattices, rafts, and scaffolds: domain regulation of receptor signaling at the plasma membrane. J Cell Biol (2009) 185(3):381-5. doi:10.1083/jcb.200811059
59. Morris S, Ahmad N, André S, Kaltner H, Gabius H-J, Brenowitz M, et al. Quaternary solution structures of galectins-1, -3, and -7. Glycobiology (2004) 14(3):293-300. doi:10.1093/glycob/cwh029
60. Garner O, Baum L. Galectin-glycan lattices regulate cell-surface glycoprotein organization and signalling. Biochem Soc Trans (2008) 36(Pt 6):1472-7. doi:10.1042/BST0361472
61. Rabinovich G, Toscano M, Jackson S, Vasta GR. Functions of cell surface galectin-glycoprotein lattices. Curr Opin Struct Biol (2007) 17(5):513-20. doi:10.1016/j.sbi.2007.09.002
62. Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell (2011) 144(5):646-74. doi:10.1016/j.cell.2011.02.013
63. Talmadge J, Fidler I. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res (2010) 70(14):5649-69. doi:10.1158/0008-5472.CAN-10-1040
64. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell (2011) 147(5):992-1009. doi:10.1016/j.cell.2011.11.016
65. Warfield P, Makker P, Raz A, Ochieng J. Adhesion of human breast carcinoma to extracellular matrix proteins is modulated by galectin-3. Invasion Metastasis (1997) 17(2):101-12.
66. O'Driscoll L, Linehan R, Liang Y, Joyce H, Oglesby I, Clynes M. Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro. Anticancer Res (2002) 22(6A):3117-25.
67. Melo F, Butera D, Junqueira M, Hsu D, da Silva AM, Liu F-T, et al. The promigratory activity of the matricellular protein galectin-3 depends on the activation of PI-3 kinase. PLoS One (2011) 6(12):e29313. doi:10.1371/journal.pone.0029313
68. Kim S-J, Shin J-Y, Lee K-D, Bae Y-K, Choi I-J, Park S, et al. Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1). PLoS One (2011) 6(9):e25103. doi:10.1371/journal.pone.0025103
69. Nangia-Makker P, Balan V, Raz A. Regulation of tumor progression by extracellular galectin-3. Cancer Microenviron (2008) 1(1):43-51. doi:10.1007/s12307-008-0003-6
70. Lagana A, Goetz J, Cheung P, Raz A, Dennis J, Nabi I. Galectin binding to Mgat5-modified N-glycans regulates fibronectin matrix remodeling in tumor cells. Mol Cell Biol (2006) 26(8):3181-93. doi:10.1128/MCB.26.8.3181-3193.2006
71. Goetz J, Joshi B, Lajoie P, Strugnell S, Scudamore T, Kojic L, et al. Concerted regulation of focal adhesion dynamics by galectin-3 and tyrosine-phosphorylated caveolin-1. J Cell Biol (2008) 180(6):1261-75. doi:10.1083/jcb.200709019
72. Shankar J, Wiseman S, Meng F, Kasaian K, Strugnell S, Mofid A, et al. Coordinated expression of galectin-3 and caveolin-1 in thyroid cancer. J Pathol (2012) 228(1):56-66. doi:10.1002/path.4041
73. Zhao Q, Barclay M, Hilkens J, Guo X, Barrow H, Rhodes J, et al. Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Mol Cancer (2010) 9:154. doi:10.1186/1476-4598-9-154
74. Zhao Q, Guo X, Nash G, Stone P, Hilkens J, Rhodes J, et al. Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. Cancer Res (2009) 69(17):6799-806. doi:10.1158/0008-5472.CAN-09-1096
75. Glinsky V, Glinsky G, Rittenhouse-Olson K, Huflejt M, Glinskii O, Deutscher S, et al. The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res (2001) 61(12):4851-7. 76. Shekhar M, Nangia-Makker P, Tait L, Miller F, Raz A. Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol (2004) 165(6):1931-41. doi:10.1016/S0002-9440(10)63245-2
76. Shekhar M, Nangia-Makker P, Tait L, Miller F, Raz A. Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol (2004) 165(6):1931-41. doi:10.1016/S0002-9440(10)63245-2
77. Moisa A, Fritz P, Eck A, Wehner HD, Mürdter T, Simon W, et al. Growth/adhesion-regulatory tissue lectin galectin-3: stromal presence but not cytoplasmic/nuclear expression in tumor cells as a negative prognostic factor in breast cancer. Anticancer Res (2007) 27(4B):2131-40.
78. Chen C, Duckworth C, Zhao Q, Pritchard D, Rhodes J, Yu L-G. Increased circulation of galectin-3 in cancer induces secretion of metastasis-promoting cytokines from blood vascular endothelium. Clin Cancer Res (2013) 19(7):1693-704. doi:10.1158/1078-0432.CCR-12-2940
79. Polyak K, Kalluri R. The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol (2010) 2(11):a003244. doi:10.1101/cshperspect.a003244
80. Bissell M, Hines W. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med (2011) 17(3):320-9. doi:10.1038/nm.2328
81. Henderson N, Mackinnon A, Farnworth S, Poirier F, Russo F, Iredale J, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A (2006) 103(13):5060-5. doi:10.1073/pnas.0511167103
82. Sioud M, Mobergslien A, Boudabous A, Fløisand Y. Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scand J Immunol (2010) 71(4):267-74. doi:10.1111/j.1365-3083.2010.02378.x
83. Henderson N, Mackinnon A, Farnworth S, Kipari T, Haslett C, Iredale J, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol (2008) 172(2):288-98. doi:10.2353/ajpath.2008.070726
84. Chaffer C, Weinberg R. A perspective on cancer cell metastasis. Science (2011) 331(6024):1559-64. doi:10.1126/science.1203543
85. Nangia-Makker P, Thompson E, Hogan C, Ochieng J, Raz A. Induction of tumorigenicity by galectin-3 in a nontumorigenic human breast-carcinoma cell-line. Int J Oncol (1995) 7(5):1079-87.
86. Ochieng J, Green B, Evans S, James O, Warfield P. Modulation of the biological functions of galectin-3 by matrix metalloproteinases. Biochim Biophys Acta (1998) 1379(1):97-106. doi:10.1016/S0304-4165(97)00086-X
87. Nangia-Makker P, Raz T, Tait L, Hogan V, Fridman R, Raz A. Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers. Cancer Res (2007) 67(24):11760-8. doi:10.1158/0008-5472.CAN-07-3233
88. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol (2009) 86(5):1065-73. doi:10.1189/jlb.0609385
89. Dragomir A-CD, Sun R, Choi H, Laskin J, Laskin D. Role of galectin-3 in classical and alternative macrophage activation in the liver following acetaminophen intoxication. J Immunol (2012) 189(12):5934-41. doi:10.4049/jimmunol.1201851
90. Colnot C, Fowlis D, Ripoche M, Bouchaert I, Poirier F. Embryonic implantation in galectin 1/galectin 3 double mutant mice. Dev Dyn (1998) 211(4):306-13. doi:10.1002/(SICI)1097-0177(199804)211:4<306::AID-AJA2>3.0.CO;2-L
91. Oliveira F, Chammas R, Ricon L, Fermino M, Bernardes E, Hsu D, et al. Galectin-3 regulates peritoneal B1-cell differentiation into plasma cells. Glycobiology (2009) 19(11):1248-58. doi:10.1093/glycob/cwp120
92. Colnot C, Ripoche M, Milon G, Montagutelli X, Crocker P, Poirier F. Maintenance of granulocyte numbers during acute peritonitis is defective in galectin-3-null mutant mice. Immunology (1998) 94(3):290-6. doi:10.1046/j.1365-2567.1998.00517.x
93. Hsu D, Yang R, Pan Z, Yu L, Salomon D, Fung-Leung W, et al. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol (2000) 156(3):1073-83. doi:10.1016/S0002-9440(10)64975-9
94. Oliveira F, Brand C, Paula A, Arcanjo K, Hsu D, Liu F-T, et al. Lack of galectin-3 disturbs mesenteric lymph node homeostasis and B cell niches in the course of Schistosoma mansoni infection. PLoS One (2011) 6(5):e19216. doi:10.1371/journal.pone.0019216
95. Brand C, Oliveira F, Takiya C, Palumbo A, Hsu D, Liu F-T, et al. The involvement of the spleen during chronic phase of Schistosoma mansoni infection in galectin-3-/- mice. Histol Histopathol (2012) 27(8):1109-20.
96. Zou J, Glinsky V, Landon L, Matthews L, Deutscher S. Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion. Carcinogenesis (2005) 26(2):309-18. doi:10.1093/carcin/bgh329
97. John C, Leffler H, Kahl-Knutsson B, Svensson I, Jarvis G. Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin Cancer Res (2003) 9(6):2374-83.
98. Yamaki S, Fujii T, Yajima R, Hirakata T, Yamaguchi S, Fujisawa T, et al. Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer. Surg Today (2013) 43(8):901-5. doi:10.1007/s00595-012-0378-3
99. van den Brûle F, Califice S, Castronovo V. Expression of galectins in cancer: a critical review. Glycoconj J (2004) 19(7-9):537-42. doi:10.1023/B:GLYC.0000014083.48508.6a
100. Volante M, Bozzalla-Cassione F, Orlandi F, Papotti M. Diagnostic role of galectin-3 in follicular thyroid tumors. Virchows Arch (2004) 444(4):309-12. doi:10.1007/s00428-004-0993-5
101. Balan V, Wang Y, Nangia-Makker P, Kho D, Bajaj M, Smith D, et al. Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget (2013) 4(4):542-9.
102. Vidi P-A, Bissell M, Lelièvre S. Three-dimensional culture of human breast epithelial cells: the how and the why. Methods Mol Biol (2013) 945:193-219. doi:10.1007/978-1-62703-125-7_13